Investor directory
Abingworth
Abingworth seeks to invest in game-changing life science companies that have the potential to materially improve patients' lives.
What they invest in
Stages
SeedSeries ASeries B
Sectors
Biotech & PharmaHealthTech
Geographies
North AmericaEurope
The facts
- Typical cheque
- €1M – €30M
- Headquarters
- London, United Kingdom
- Founded
- 1973
Portfolio
CRISPR Therapeutics (NAS: CRSP)Phathom Pharmaceuticals (NAS: PHAT)Scorpion TherapeuticsIambicR1 TherapeuticsAllotera TherapeuticsVaxcyte (NAS: PCVX)Ceryvyn Therapeutics (ASX: CYV)Solve TherapeuticsAtsena TherapeuticsSoteria BiotherapeuticsTimberlyne TherapeuticscAMPfield TherapeuticsAntares TherapeuticsExicure (NAS: XCUR)Escient PharmaceuticalsGlycomineReneo PharmaceuticalsAdicet Bio (NAS: ACET)Effector Therapeutics (OTCM: EFTR)AdvanCellNido BiosciencesIFM TreOnKure Therapeutics (NAS: OKUR)
and 23 more
Does Abingworth fit your round?
Oka scores this fund against your actual raise — stage, sector, cheque size and traction — and shows you who can introduce you.
Check your matchAre you Abingworth? Tell us what to correct and we will update this page.